PAST ARTICLE SEARCH
Search iPS Cells & Regenerative Medicine Articles
Find iPS Cells & Regenerative Medicine coverage by technology, company, or a free keyword search.
587 published articles67 technology terms20 companies
Search by Technology
Select a technology term to view related iPS Cells & Regenerative Medicine articles.
Search by Company
Select a company to view related iPS Cells & Regenerative Medicine articles.
Keyword Search
Search titles and article content within iPS Cells & Regenerative Medicine.
Results
Matching articles will appear here.
Select a technology term or company, or enter a keyword.
Latest articles in iPS Cells & Regenerative Medicine
The 100 most recent articles. Use the search above to filter by technology, company, or keyword.
- iPS Cells & Regenerative Medicine Weekly Report October 11, 20262026-10-11
- Daraxonrasib: First RAS inhibitor FDA approval specs for 20262026-10-11
- 3D Bioprinting: Multi-layered tumor organoid specs for 20262026-10-11
- Aglatimagene: Candel Therapeutics NSCLC Phase 2a 2026 roadmap2026-10-11
- 3D Bioprinting: Tsinghua University vascular organoid specs2026-10-11
- FAYUVI: Ultragenyx AAV9 gene therapy FDA approval and specs2026-10-11
- Lonvo-z: Intellia Therapeutics’ FDA approval for CRISPR therapy2026-10-11
- Sartorius Eveo: Cell therapy costs cut 90% to under $40,0002026-10-11
- VIPR system: Jennifer Doudna’s discovery of CRISPR ancestor2026-10-11
- Sanfilippo Syndrome Type A: FDA approves first gene therapy2026-10-11
- APOE4 explained: Reversible weakness in Alzheimer’s risk gene2026-10-11
- iPS Cells & Regenerative Medicine Weekly Report October 4, 20262026-10-04
- SonoThera’s Non-Viral RIPPLE Gene Therapy Boosts Dystrophin Expression by 290% in Macaques; Clinical Trials Slated for Mid-20272026-10-04
- FDA Approves First AAV Gene Therapy UX111 for Sanfilippo Syndrome Type A, Offering New Hope for Pediatric Neurodegeneration2026-10-04
- Beam Therapeutics’ In Vivo Base Editor BEAM-302 Increases Functional AAT by 93% in AATD Patients, Transforming Long-Term Disease Risk to Carrier Status2026-10-04
- Gut Metabolites Impact CAR-T Therapy Efficacy: Butyrate and Indoles Linked to Enhanced Long-Term Remission and Survival in 129 Patient Clinical Data2026-10-04
- CAR-T Cell Therapy Combined with Menin Inhibitors Achieves Over 90% Relapse-Free Survival in KMT2A-Rearranged Infant Leukemia2026-10-04
- Meta-Analysis Integrates Safety and Efficacy of CAR T Therapy in Solid Malignancies, Lymphodepletion Enhances Response Rates2026-10-04
- Astellas Advances Hypoimmune iPSC Therapies for Retinal Diseases via Gene-Edited Universal Cell Technology to Overcome Immune Rejection2026-10-04
- IMS 2026 Reveals Real-World Data: eque-cel CAR-T Achieves 95.9% ORR in Relapsed/Refractory Multiple Myeloma2026-10-04
- Engineered Cord Blood CAR-NK Cells Achieve Clinical Responses in CD19+ B-Cell Malignancies with Minimized Severe Toxicity2026-10-04
- MIT and Johns Hopkins Develop 3D-Printed Handheld Microfluidic Device: Selectively Harvests Live Cells from Tissue for Early Cancer Detection and Personalized Therapy2026-10-04
- GC Cell’s CD5 CAR-NK Candidate ‘GCC2005’ Achieves 62.5% ORR in Phase 1a for NK/T-Cell Lymphoma, Demonstrating Long-Term Remission and Favorable Safety2026-10-04
- Functional 3D Bioprinted Kidney Organoids Demonstrate Metabolic Filtration, Advancing Organ Transplant Alternatives2026-10-04
- iPS Cells & Regenerative Medicine Weekly Report September 26, 20262026-09-26
- Boehringer Ingelheim: $1B AI RNA splicing oncology roadmap with Envisagenics2026-09-26
- Sasineprocel: Aspen Neuroscience Parkinson’s therapy data for 20262026-09-26
- CAR T-cells: Alpha-2,3-Sialylation function explained via BioRxiv2026-09-26
- Fayuvi: FDA approval and specs for MPS IIIA gene therapy in 20262026-09-26
- Evotec: iPSC-derived CAR γδ T-cell manufacturing specs for 20262026-09-26
- Anito-cel: Phase 1 trial specs and 100% response rate for CAR-T2026-09-26
- Made Scientific: 85,000 sq-ft cell therapy facility acquisition2026-09-26
- FDA vs EMA: CGT manufacturing and potency assay requirements2026-09-26
- Ryoncil: Mesoblast’s new FDA potency assay specs for GVHD drug2026-09-26
- iPSC Cell Therapy: 2026 roadmap for BeiGene, BlueRock and Fate2026-09-26
- iPS Cells & Regenerative Medicine Weekly Report September 20, 20262026-09-20
- Ori Biotech Secures $120M, 10-Year Partnership for Automated Cell Therapy Manufacturing; Vyriad’s In Vivo CAR-T Clears IND2026-09-20
- Vertex Pharmaceuticals Initiates Phase I/II for Type 1 Diabetes Cell Therapy, Expands Renal Pipeline at Morgan Stanley Conference2026-09-20
- Tempest Therapeutics Licenses Senlang’s In Vivo CAR-T Platform, Targeting Relapsed/Refractory Multiple Myeloma with Dual BCMA/GPRC5D Approach in Phase I Trial2026-09-20
- Indian Health Ministry Issues Advisory to States, UTs to Regulate Stem Cell Therapy; Limits Autism Application to Clinical Trials2026-09-20
- UA Little Rock Secures Grant to Develop 3D Tissue Scaffold Replicating Human Intestinal Villi-Crypt Structures2026-09-20
- BioInformant Report Outlines 2026 iPSC-Derived Cell Therapeutic Pipeline, Highlighting Safety Challenges and Key Developers2026-09-20
- GC Cell’s CAR-NK Therapy GCC2005 Approved for Compassionate Use in Refractory T-Cell Lymphoma at SNUH, South Korea2026-09-20
- EU-Funded PRISM-LT Project Accelerates Living Tissue Growth with Nature-Inspired 3D Bioprinting, Paving Way for Leukemia Research and Cultivated Meat Production2026-09-20
- Beam Therapeutics Pursues Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Citing Positive Phase 1/2 Clinical Data2026-09-20
- 3-Year-Old’s Metastatic Liver Cancer Disappears After Two Doses of Experimental CAR T-Cell Therapy2026-09-20
- CRISPR Therapeutics Anticipates CASGEVY Market Expansion and Key Pipeline Catalysts by Year-End 20262026-09-20
- CRISPR Therapeutics Forges Long-Term Growth with In Vivo Editing and Gene Insertion Following CASGEVY Approval2026-09-20
- iPS Cells & Regenerative Medicine Weekly Report September 13, 20262026-09-13
- Biotech M&A Heats Up: Merck KGaA Acquires Bio-Techne for $11.3B to Bolster Life Science Tools for Cell and Gene Therapy2026-09-13
- Cell Therapy Startups Exceed $36 Billion in Cumulative Fundraising, Top Companies Secure Over $1 Billion Each2026-09-13
- iPSC Product Quality Defined in Differentiation: Core of Process Development for GMP Manufacturing2026-09-13
- Merck KGaA to Acquire Bio-Techne for $11.3 Billion, Bolstering Life Science Tools for Cell and Gene Therapy Workflows2026-09-13
- Typewriter Therapeutics Secures $56M Series A for In Vivo CAR-T, Aiming to Streamline Cell Therapy Manufacturing2026-09-13
- CAR T-Cell Therapy Clinical Trial Landscape for Non-Hodgkin Lymphoma Expands with Over 70 Companies Developing Next-Gen Treatments2026-09-13
- Global Cell and Gene Therapy Manufacturing Services Market to Surge to $31.3 Billion by 2035, Driven by Regulatory Modernization2026-09-13
- 2026 iPSC Industry Report: Allogeneic Therapies Surpass Autologous, Diabetes, Parkinson’s, AMD Clinical Trials Progress2026-09-13
- Cell and Gene Therapy GMP Services Market Forecast to Reach $5.88 Billion by 2030, Growing at 18.9% CAGR2026-09-13
- Beam Therapeutics’ Base Editing Therapy BEAM-302 Shows Rapid, Sustained AAT Increase in Phase 1/2 for Alpha-1 Antitrypsin Deficiency, Targets Accelerated Approval2026-09-13
- Sana Biotechnology Targets 2026 IND for iPSC-Derived Hypoimmune Pancreatic Islet Cell Therapy SC451 in Type 1 Diabetes2026-09-13
- FDA Clears Clinical Trial for CAR T-Cell Therapy in Advanced Colorectal Cancer, Expanding Solid Tumor Reach2026-09-13
- Cellipont Bioservices Supports Six Cell Therapy Programs Towards 2026 IND Filings, Highlighting CDMO Market Growth2026-09-13
- Fate Therapeutics to Detail iPSC-Derived Cellular Immunotherapy Pipeline at Cantor Global Healthcare Conference2026-09-13
- Fate Therapeutics to Present Encore Clinical Data for iPSC-Derived FT819 in Systemic Scleroderma2026-09-13
- CRISPR Therapeutics to Detail Pipeline Progress at Morgan Stanley Global Healthcare Conference2026-09-13
- IV Exosome Therapy: Under Investigation for Cell Behavior Modulation and Anti-Inflammation, FDA Not Yet Approved2026-09-13
- Nanjing Drum Tower Hospital Engineers Stem Cell Patch for Cardiac Regeneration: A New Frontier in Heart Failure Treatment2026-09-13
- BrainChild Bio Secures $116M, Earns FDA Breakthrough Designations for CAR-T Therapy Against Pediatric Brain Cancer DIPG2026-09-13
- Harro Höfliger’s Robust Database Optimizes Product Development, Resolving Regenerative Medicine Manufacturing Bottlenecks2026-09-13
- Exosome Therapy Revolutionizes Skin Treatment: Promotes Cell Regeneration and Anti-Inflammation Without Physical Injury2026-09-13
- The Next Frontier in Hematology: China’s Leadership in CAR-T and CRISPR Gene Editing2026-09-13
- Parkinson’s Regenerative Medicine Milestone: iPSC-Derived Dopamine Precursors Safely Transplanted in First-in-Human Trial2026-09-13
- Rewriting Sickle Cell Disease: The Promise of In Vivo Gene Editing and the Global Equity Challenge2026-09-13
- Breakthrough: Schwann Cell Exosomes Dramatically Improve Recovery from Severe Peripheral Nerve Injuries2026-09-13
- CRISPR Gene Editing: Engineering Durable Cures for Congenital Diseases through Stem Cell and Liver Targeting2026-09-13
- Autologous iPSCs from PAD Patients Demonstrate Therapeutic Equivalence to Healthy Donors, Propelling Personalized Vascular Regeneration2026-09-13
- Next-Gen Brain Organoids Reveal How APOE4 Astrocytes Drive Alpha-Synuclein Pathology, Unlocking New Therapeutic Targets2026-09-13
- Watchmaker Genomics Bolsters Global Supply Chain, Doubles Manufacturing Capacity with 100,000 Sq Ft Boulder Facility2026-09-13
- Scaling Viral Vector Manufacturing: The Bottleneck to Gene Therapy’s Broader Impact2026-09-13
- Twenty Years of iPSCs: From Bespoke Models to Standardized Engineered Biologics2026-09-13
- Comprehensive Analysis Reveals iPSC Potential in CAR-T Therapy for Cancer, Highlights Key Challenges2026-09-13
- Single-Dose CRISPR Therapy Slashes LDL Cholesterol by 52.5%, Triglycerides by 47.8% in Landmark Phase 1 Trial2026-09-13
- iPS Cells & Regenerative Medicine Weekly Report September 6, 20262026-09-06
- Genprex Taps Andelyn Biosciences to Accelerate Manufacturing Scale-Up for Diabetes Gene Therapy Program2026-09-06
- The Unspoken Challenge: Cell Therapy Developers Lack Full Product Understanding at Clinical Stage2026-09-06
- Cellipont Bioservices’ Texas Facility Propels Six Client Cell Therapy Programs to Expected 2026 IND Submissions2026-09-06
- Biotech Alliances Surge: Alteogen-Novartis Subcutaneous Drug Delivery Deal and NewBiologix-Synastra Gene Therapy Manufacturing Partnership Highlight Industry Trends2026-09-06
- Overcoming Commercialization Hurdles for iPSC Therapeutics: Regulatory Compliance and Accessible Manufacturing Strategies2026-09-06
- Cell Therapy Market Sees 26% Revenue Growth, Driven by Commercial Successes and Strategic Investment in Scalable Manufacturing2026-09-06
- Century Therapeutics Seeks Director to Lead Large-Scale Cell Therapy Process Development for Clinical and Commercial Programs2026-09-06
- UniQure Files for FDA Approval of Huntington’s Gene Therapy AMT-130, Pursuing Breakthrough for Neurological Disorder2026-09-06
- CRISPR Therapeutics Reports Deep, Durable Lipid Lowering from In Vivo Gene Editor CTX310 in Phase 1a Trial2026-09-06
- Cell and Gene Therapy Sector Shifts to “Execution Discipline” Amidst Manufacturing Platform Scrutiny and Autoimmune CAR-T Safety Concerns2026-09-06
- BioNTech and Genentech Terminate Phase 2 Personalized Cancer Vaccine Trial Due to Survival Imbalance2026-09-06
- Novartis Halts Autoimmune CAR-T Trials After Three Patient Deaths, Sparking Safety Debate2026-09-06
- Winship Cancer Institute Launches Cellular Therapy Initiative to Scale Next-Gen Cancer Treatment Development2026-09-06
- Ultragenyx’s Phase 3 Angelman Syndrome Trial Fails, Triggering 43% Stock Plunge2026-09-06
- Northway Biotech Launches €61M Cell Therapy CDMO in Lithuania, Scaling Advanced Biologics for Global Demand2026-09-06
- 3D Bioprinting Market Drives Regenerative Medicine and Biomedical Innovation, Accelerated by AI Integration2026-09-06
- TScan Therapeutics Pivots to In Vivo TCR-T for Solid Tumors, Cuts 75% of Staff2026-09-06